Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
TrivarX Limited ( (AU:TRI) ) has issued an update.
TrivarX Limited has made significant progress in advancing its MEB-001 algorithm towards FDA approval, having finalized plans for a pivotal trial and strengthened clinical trial design confidence in a meeting with the FDA. The company also developed a new algorithm that broadens its market reach by using heart rate data for sleep staging and depressive episode screening, which showed promising results in initial testing. These developments open up new market opportunities outside traditional sleep centers, potentially impacting stakeholders by expanding the total addressable market and enhancing solution applications.
More about TrivarX Limited
TrivarX Limited is a company operating in the healthcare industry, focusing on innovative AI-backed solutions for mental health screening. Their primary product, MEB-001, is an algorithm designed to assist in the diagnosis of current Major Depressive Episodes using data from sleep studies, with a significant market focus on sleep clinics, cardiac monitoring, military, and wearable technologies.
YTD Price Performance: -13.33%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.82M
See more data about TRI stock on TipRanks’ Stock Analysis page.
